Abstract 1326P
Background
In patients with metastatic Non Small Cell Lung cancer (NSCLC), the presence of liver metastases has been implicated as a poor prognostic factor. On the other hand, few datas are published about the prognostic factor of bone metastasis with check-point inhibitors. We investigated the association between sites of metastatic disease and clinical outcomes in stage-IIIb or IV NSCLC patients treated by Nivolumab in second line treatment or more.
Methods
Analyze of a multicenter, observational, prospective study. Primary outcome: overall survival (OS) after first injection of nivolumab according to the presence of liver or bone metastasis.
Results
Between July 2016 and July 2017, 28 centers prospectively included 485 patients, median age: 64.3 years; men: 70.8%; smokers or ex-smokers: 91.6%; PS: 0/1: 81.2%; adenocarcinoma: 62.3% (KRAS: 27.5%); first-line platinum-based chemotherapy: 91.3% (doublet: 76.5%, triplet: 14.8%, maintenance chemotherapy: 53.6%), Nivolumab was administrated as second line therapy: 63.7% (n=308) of the cases. At nivolumab initiation, 63.9% (n=309) had >1 metastasis sites, including cerebral: 15.1% (n=73), liver 32% (n=155) and bone metastasis: 26.1% (n=126). Median PFS and OS of the cohort were 2 (95%CI: 1.9-2.1) and 9.7 (95%CI: 8.5-11.4) months respectively. There is no significant difference for OS in patients with and without bone metastasis: 10.1 (95%CI: 6.3-13.3) and 9.5 (95%CI: 8.4-11.2), p=0.62, but a significant difference for patients with and without liver metastasis: 5.5 (95%CI: 3.7-9.8) and 10 (95%CI: 8.6-12.1) months, p=0.004, respectively.
Conclusions
Bone metastases do not appear to impact overall survival of advanced NSCLC treated by Nivolumab in contrast to some previous retrospective studies. On the other hand, liver metastases are associated with poorer survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
GFPC.
Funding
Has not received any funding.
Disclosure
C. Decroisette: Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: BMS; Advisory/Consultancy: MSD; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Pfizer. F. Guisier: Honoraria (self): AstraZeneca; Honoraria (self): BMS; Honoraria (self): Merck; Honoraria (self): Roche. O. Bylicki: Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: AstraZeneca. M. Geier: Advisory/Consultancy: BMS; Advisory/Consultancy: MSD; Advisory/Consultancy: AstraZeneca. A. Vergnenegre: Honoraria (self): MSD; Honoraria (self): Hoffman Roche; Honoraria (self): AstraZeneca; Honoraria (self): Pierre Fabre Oncology; Honoraria (self): Boehringer Ingelheim. All other authors have declared no conflicts of interest.